Delving into the Latest Updates on Ipilimumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti CTLA-4 monoclonal antibody, Anti-CTLA-4 Mab, Ipilimumab (Genetical Recombination)

+ [16]

Target

CTLA4

Mechanism

CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [13]

Active Indication

Unresectable Esophageal Squamous Cell CarcinomaEsophageal CarcinomaMesothelioma+ [296]

Inactive Indication

Acute lymphoblastic leukemia recurrentAcute myeloid leukaemia with 11q23 abnormalityAcute Promyelocytic Leukemia+ [91]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

National Cancer Institute

Bristol Myers Squibb Co.Bristol-Myers Squibb Pharma EEIG

+ [9]

Inactive Organization

Checkmate Pharmaceuticals, Inc.National Institutes of Health Clinical Center

Syndax Pharmaceuticals, Inc.

+ [4]

Drug Highest PhaseApproved

First Approval Date

US (25 Mar 2011),

Melanoma

RegulationFast Track (US), Accelerated Approval (US), Priority Review (CN), Breakthrough Therapy (CN), Conditional marketing approval (CN), Orphan Drug (KR), Priority Review (AU), Breakthrough Therapy (US), Orphan Drug (US)

Login to view timeline

Gene Sequence

Sequence Code 143797L

Source: *****

Sequence Code 9060585H

Source: *****

This is a phase 2 stratified, randomized, multicenter, study investigating the efficacy of a triplet arm treating with nivolumab 480 mg every 4 weeks (Q4W), relatlimab 160 mg Q4W and ipilimumab 1 mg/kg every 8 weeks (Q8W) intravenous (IV) versus a doublet arm treating with nivolumab 480 mg Q3W and ipilimumab 1mg/kg Q3W IV in first-line advanced RCC.

Start Date01 May 2025

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

NCT06712927 / Not yet recruitingPhase 2IIT

A Multicenter, Phase II Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

This is a multicenter, phase II trial of relatlimab (rela), nivolumab (nivo), and ipilimumab (ipi) in patients with asymptomatic and symptomatic melanoma brain metastases.

Start Date01 Feb 2025

Sponsor / Collaborator

Stanford University

100 Clinical Results associated with Ipilimumab

Login to view more data

100 Translational Medicine associated with Ipilimumab

Login to view more data

100 Patents (Medical) associated with Ipilimumab

Login to view more data

5,044

Literatures (Medical) associated with Ipilimumab

01 Dec 2025·Current Neurology and Neuroscience Reports

Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review

Review

Author: Gowda, Maya ; Camacho, Alejandra M ; Ranjan, Tulika ; Ahluwalia, Manmeet S ; Podder, Vivek

PURPOSE OF REVIEW:

Advancements in precision medicine have shifted the treatment paradigm of brain metastases (BM) from non-small cell lung cancer (NSCLC), breast cancer, and melanoma, especially through targeted therapies focused on specific molecular drivers. These novel agents have improved outcomes by overcoming challenges posed by the blood-brain barrier (BBB) and resistance mechanisms, enabling more effective treatment of BM.

RECENT FINDINGS:

In NSCLC, therapies such as osimertinib have improved efficacy in treating EGFR-mutant BM, with emerging combinations such as amivantamab and lazertinib offering promising alternatives for patients resistant to frontline therapies. In HER2-positive breast cancer, significant advancements with tucatinib and trastuzumab deruxtecan (T-DXd) have transformed the treatment landscape, achieving improved survival and intracranial control in patients with BM. Similarly, in triple-negative breast cancer (TNBC), novel therapies such as sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) offer new hope for managing BM. For melanoma, the combination of immune checkpoint inhibitors such as nivolumab and ipilimumab has proven effective in enhancing survival for patients with BM, both in BRAF-mutant and wild-type cases. Developing targeted therapies penetrating the BBB has revolutionized BM treatment by targeting key drivers like EGFR, ALK, HER2, and BRAF. Despite improved survival, challenges persist, particularly for patients with resistant genetic alterations. Future research should optimise combination therapies, overcome resistance, and refine treatment sequencing. Continued emphasis on personalized, biomarker-driven approaches offers the potential to further improve outcomes, even for complex cases.

15 Jan 2025·INTERNATIONAL JOURNAL OF CANCER

Association between immune checkpoint inhibitor and cytomegalovirus infection: A pharmacovigilance study based on the adverse event reporting system

Article

Author: Saisyo, Atsuyuki ; Okada, Naoto ; Yanagi, Tomoyuki ; Kitahara, Takashi ; Tamura, Miho ; Ozaki, Masakazu ; Sasaki, Takaaki

Abstract:

Immune checkpoint inhibitor (ICI)‐induced adverse events due to excessive immune stimulation are problematic in immunotherapy. The activation of viral infection triggered by ICI‐induced dysregulated immunity has been proposed; however, this association remains inconsistent. This study investigated the association between ICI administration and cytomegalovirus (CMV) infections, a pathogen linked to immune abnormalities and reactivation, using the Food and Drug Administration Adverse Event Reporting System. We used the crude data set and immunocompromise‐free data set from the fourth quarter of 2012 to 2023. The disproportionality between CMV infection and ICI was analyzed using reporting odds ratio (ROR) and information component (IC) methodologies. Disproportionality between ipilimumab and nivolumab combination case and CMV infection was observed in the crude (ROR: 2.83, 95% confidence interval [CI]: 2.32–3.47; IC: 1.48, 95% CI: 1.14–1.73) and immunocompromise‐free data set (ROR: 1.76, 95% CI: 1.33–2.33; IC: 0.80, 95% CI: 0.33–1.14), whereas disproportionality between other ICI and CMV infection was not observed in the immunocompromise‐free data set. Multiple sensitivity analyses and time‐scan analysis also revealed the consistent disproportionality between ipilimumab and nivolumab combination cases and CMV infection, regardless of the host's immune status. While further research is warranted to validate our findings, these results highlight new insights into ICI‐induced viral infections and suggest the importance of considering the possibility of CMV infections during ipilimumab and nivolumab combination therapy, regardless of the host's immune status.

31 Dec 2024·Cancer biology & therapy

Understanding and overcoming resistance to immunotherapy in genitourinary cancers

Review

Author: Yildirim, Ahmet ; Kalemoglu, Ecem ; Evans, Sean T ; Jani, Yash ; Jansen, Caroline S ; Bilen, Mehmet Asim

The introduction of novel immunotherapies has significantly transformed the treatment landscape of genitourinary (GU) cancers, even becoming the standard of care in some settings. One such type of immunotherapy, immune checkpoint inhibitors (ICIs) like nivolumab, ipilimumab, pembrolizumab, and atezolizumab play a pivotal role by disturbing signaling pathways that limit the immune system's ability to fight tumor cells. Despite the profound impact of these treatments, not all tumors are responsive. Recent research efforts have been focused on understanding how cancer cells manage to evade the immune response and identifying the possible mechanisms behind resistance to immunotherapy. In response, ICIs are being combined with other treatments to reduce resistance and attack cancer cells through multiple cellular pathways. Additionally, novel, targeted strategies are currently being investigated to develop innovative methods of overcoming resistance and treatment failure. This article presents a comprehensive overview of the mechanisms of immunotherapy resistance in GU cancers as currently described in the literature. It explores studies that have identified genetic markers, cytokines, and proteins that may predict resistance or response to immunotherapy. Additionally, we review current efforts to overcome this resistance, which include combination ICIs and sequential therapies, novel insights into the host immune profile, and new targeted therapies. Various approaches that combine immunotherapy with chemotherapy, targeted therapy, vaccines, and radiation have been studied in an effort to more effectively overcome resistance to immunotherapy. While each of these combination therapies has shown some efficacy in clinical trials, a deeper understanding of the immune system's role underscores the potential of novel targeted therapies as a particularly promising area of current research. Currently, several targeted agents are in development, along with the identification of key immune mediators involved in immunotherapy resistance. Further research is necessary to identify predictors of response.

945

News (Medical) associated with Ipilimumab

12 Dec 2024

·www.accesswire.com

BioInvent Announces First Patient Enrolled in Phase 1b/2a Study of BI-1607 in Combination with Ipilimumab and KEYTRUDA (Pembrolizumab) in Patients with Unresectable or Metastatic Melanoma

Study to evaluate safety and anti-tumoral activity of anti-FcgRIIB antibody BI-1607 with anti-CTLA-4: ipilimumab, in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA)( anti-PD-1 therapy, KEYTRUDA® (pembrolizumab); initial data expected in H2 2025Data from Phase 1 study in combination with trastuzumab previously demonstrated BI-1607 is safe, well tolerated and achieves full receptor occupancy during the treatment interval at several dose levels; preclinical data show BI-1607 enables lower anti-CTLA-4 dosing with improved survivalClinical supply agreement for KEYTRUDA® in place with MSDLUND, SE / ACCESSWIRE / December 12, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has enrolled the first patient in the Phase1b/2a study evaluating the safety and anti-tumoral activity of its second FcyRIIB-blocking antibody BI-1607 in combination with ipilimumab and KEYTRUDA® (pembrolizumab) in patients with unresectable or metastatic melanoma.The study will incorporate four cohorts in which two different dose levels of BI-1607 will be tested with two different dose levels of the CTLA-4 antibody ipilimumab, 3 mg/kg, approved for the treatment of melanoma, and the lower dose 1 mg/kg, in combination with a 200 mg flat dose of pembrolizumab in patients with unresectable or metastatic melanoma previously treated with anti-PD-1/L1.Approximately 35 patients will be enrolled in 10 to 12 sites located in the UK, Germany and Spain with first data expected in H2 2025. In July 2024, BioInvent signed a clinical supply agreement with MSD International Business GmbH, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA to provide KEYTRUDA for use in the study."The early data delivered so far by our BI-1607 program have been highly promising and we are very pleased to be advancing the asset's development with this new study," said Martin Welschof, Chief Executive Officer of BioInvent. "We have shown BI-1607 to be safe and well tolerated with signs of early clinical activity in Phase 1 evaluation in combination with trastuzumab. Additionally, our preclinical data also indicate that a regimen including BI-1607 could allow the use of lower doses of ipilimumab, potentially achieving increased tolerability and higher efficacy. We are looking forward to exploring the huge potential of this combination further and preliminary data from the study expected next year."BI-1607 is an engineered antibody that can be viewed as a platform to enhance efficacy and overcome resistance to existing cancer treatments, such as targeted monoclonal antibodies and immune checkpoint inhibitors. In December 2023, BioInvent presented first clinical data from the Phase 1 dose escalation study evaluating BI-1607 in combination with trastuzumab in subjects with HER2+ advanced solid tumors. The data demonstrated that the treatment was well tolerated, and no serious adverse events related to BI-1607 were observed. Stabilization of the disease was observed in 7 patients. Previously in 2021, BioInvent announced preclinical proof-of-concept data showing the ability of BI-1607 to overcome resistance to CTLA-4-based therapy.KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com . Follow us on the social media platform X: @BioInvent.For further information, please contact:Cecilia Hofvander, VP Investor RelationsPhone: +46 (0)46 286 85 50Email: [email protected]BioInvent International AB (publ)Co. Reg. No. Org nr: 556537-7263Visiting address: Ideongatan 1Mailing address: 223 70 LUNDPhone: +46 (0)46 286 85 50www.bioinvent.comThe press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.AttachmentsBioInvent announces first patient enrolled in Phase 1b/2a study of BI-1607 in combination with ipilimumab and KEYTRUDA (pembrolizumab) in patients with unresectable or metastatic melanomaSOURCE: BioInvent International

Phase 1Immunotherapy

09 Dec 2024

·www.drugs.com

Survival Up With Nivolumab + Ipilimumab Versus Chemo for Metastatic CRC

MONDAY, Dec. 9, 2024 -- For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer who had not previously received systemic treatment, progression-free survival is longer with nivolumab plus ipilimumab than with chemotherapy, according to a study published online in the Nov. 27 issue of the New England Journal of Medicine . Thierry Andre, M.D., from Sorbonne Université in Paris, and colleagues randomly assigned patients with unresectable or metastatic colorectal cancer and MSI-H or dMMR status according to local testing to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy with or without targeted therapies in a 2:2:1 ratio in a phase 3, open-label trial. In this prespecified interim analysis, nivolumab plus ipilimumab was compared to chemotherapy. Overall, 303 patients who had not previously received systemic treatment were randomly assigned to receive nivolumab plus ipilimumab or chemotherapy; 255 of the patients had centrally confirmed MSI-H or dMMR tumors. The researchers found that progression-free survival outcomes were significantly better with nivolumab plus ipilimumab than with chemotherapy at a median follow-up of 31.5 months (24-month progression-free survival, 72 versus 14 percent with nivolumab plus ipilimumab versus chemotherapy). The restricted mean survival time was 10.6 months longer with nivolumab plus ipilimumab versus chemotherapy at 24 months, which was consistent with the primary analysis of progression-free survival. Grade 3 or 4 treatment-related adverse events occurred in 23 and 48 percent of patients in the nivolumab plus ipilimumab and chemotherapy groups, respectively. "Progression-free survival outcomes with nivolumab plus ipilimumab were superior to those with chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer," the authors write. The study was funded by Bristol Myers Squibb and Ono Pharmaceutical; Bristol Myers Squibb manufactures nivolumab and ipilimumab.

Clinical ResultPhase 3

25 Nov 2024

·www.prnewswire.com

Innovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024

SAN FRANCISCO and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that nearly 10 accepted clinical data of its novel oncology molecules, including an oral presentation of updated Phase 1 result of its novel TOPO1i CLDN18.2 ADC (IBI343) in previously-treated pancreatic cancer, will be released at the European Society of Medical Oncology Asia (ESMO Asia) Congress 2024 from Dec 06-08, 2024, in Singapore. Details on the abstracts are listed below: Mini Oral Abstract Title: Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients with advanced pancreatic ductal adenocarcinoma (PDAC): updated results from a Phase 1 study Abstract No: 132MO Session Type and Title: Mini Oral session: Gastrointestinal tumors Presentation Time: 2024-12-07, 09:50-09:55 Presenter: Jian Zhang, Fudan University Shanghai Cancer Center, CN Abstract Title: mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody in Locally Advanced MSS CRC (BASKETⅡ): A Prospective, Single-Arm, Open-Label, Phase 2 Study Abstract No: 74MO Session Type and Title: Mini Oral session: Gastrointestinal tumors Presentation Time: 2024-12-07, 10:20-10:25 Presenter: Jun Huang, The Sixth Affiliated Hospital, Sun Yat-sen University, CN Posters Abstract Title: Anlotinib plus Sintilimab as First-line Treatment for Patients with Advanced Colorectal Cancer (APICAL-CRC): an Open-Label, Single-arm, Phase 2 study Abstract No: 75P Session Type and Title: Poster Display session Presentation Time: 2024-12-07, 17:50-18:45 Presenter: Zhan Wang, Shanghai Changzheng Hospital, The Second Affiliated Hospital of Naval Medical University, CN Abstract Title: A single-arm, multicenter, Phase 2 study of hepatic arterial infusion chemotherapy (HAIC) combined with donafenib and sintilimab as first-line treatment for unresectable intrahepatic cholangiocarcinoma (CHANCE 2203) Abstract No: 137P Session Type and Title: Poster Display session Presentation Time: 2024-12-07, 17:50-18:45 Presenter: Gaojun Teng, Zhongda Hospital, Southeast University, CN Abstract Title: FOLFOX-HAIC combined with sintilimab and bevacizumab for advanced hepatocellular carcinoma: a single-arm, Phase 2 study Abstract No: 207P Session Type and Title: Poster Display session Presentation Time: 2024-12-07, 17:50-18:45 Presenter: Bin Liang/ Zizhuo Wang, Union Hospital Tongji Medical College Huazhong University of Science and Technology, CN Abstract Title: Updated results from Phase 2 study of HAIC plus sintilimab and bevacizumab biosimilar in patients with advanced hepatocellular carcinoma (HCC) Abstract No: 214P Session Type and Title: Poster Display session Presentation Time: 2024-12-07, 17:50-18:45 Presenter: Haibin Zhang, Eastern Hepatobiliary Surgery Hospital, Third Affiliated Hospital of Naval Medical University, CN Abstract Title: Anlotinib Combined with Sintilimab Versus Chemotherapy Combined with Immunotherapy in Perioperative NSCLC: A Phase 2 Study Abstract No: 599P Session Type and Title: Poster Display session Presentation Time: 2024-12-07, 17:50-18:45 Presenter: Tianqing Chu, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN Trial in Progress abstracts (TiP) Abstract Title: A randomized, controlled, multicenter Phase 3 study of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) as neoadjuvant treatment for resectable microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colon cancer: Trial in Progress Abstract No.: 119TiP Session Type and Title: Poster Display session Presentation Time: 2024-12-07, 17:50-18:45 Presenter: Ruihua Xu, Sun Yat-sen University Cancer Center, CN Abstract Title: Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy with Cryoablation in the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Abstract No.: 722TiP Session Type and Title: Poster Display session Presentation Time: 2024-12-07, 17:50-18:45 Presenter: Zhiqiang Gao, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN Dr. Hui Zhou, Senior Vice President of Innovent, stated: "We are very pleased to present and share a robust set of clinical data at EAMO Asia 2024. Notably, we are highlighting the breakthrough potential for our TOPO1i CLDN18.2 ADC (IBI343) in pancreatic cancer, a global difficult-to-treat cancer. Consistent with the preliminary signal observed in small patient size, the data in dose expansion stage demonstrated encouraging efficacy and good safety, which reinforced our confidence in advancing its development. Given unique design of Fc-silent antibody, combined with stable linker and potent extecan payload, IBI343 pioneered in the exploration of CLDN18.2 ADC agents for PDAC treatment. As one of the few biopharmaceutical companies with both advanced technology platforms and a robust pipeline in "IO+ADC" areas, Innovent remains dedicated to transforming cancer treatment by delivering innovative, effective, and safe therapeutic options for doctors and patients." About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 11 products in the market. It has 5 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. SOURCE Innovent Biologics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Phase 1Clinical ResultADCImmunotherapy

100 Deals associated with Ipilimumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D04603	Ipilimumab	L01XC11	DB06186

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Unresectable Esophageal Squamous Cell Carcinoma	US	Bristol Myers Squibb Co.	27 May 2022
Esophageal Carcinoma	JP	Bristol-Myers Squibb KK	26 May 2022
Mesothelioma	JP	Ono Pharmaceutical Co., Ltd.	27 May 2021
Mesothelioma	JP	Bristol-Myers Squibb KK	27 May 2021
Hepatocellular Carcinoma	US	Bristol Myers Squibb Co.	10 Mar 2020
Colorectal Cancer	US	Bristol Myers Squibb Co.	16 Apr 2018
Advanced Renal Cell Carcinoma	EU	Bristol-Myers Squibb Pharma EEIG	13 Jul 2011
Advanced Renal Cell Carcinoma	IS	Bristol-Myers Squibb Pharma EEIG	13 Jul 2011
Advanced Renal Cell Carcinoma	LI	Bristol-Myers Squibb Pharma EEIG	13 Jul 2011
Advanced Renal Cell Carcinoma	NO	Bristol-Myers Squibb Pharma EEIG	13 Jul 2011
Metastatic Esophageal Squamous Cell Carcinoma	EU	Bristol-Myers Squibb Pharma EEIG	13 Jul 2011
Metastatic Esophageal Squamous Cell Carcinoma	IS	Bristol-Myers Squibb Pharma EEIG	13 Jul 2011
Metastatic Esophageal Squamous Cell Carcinoma	LI	Bristol-Myers Squibb Pharma EEIG	13 Jul 2011
Metastatic Esophageal Squamous Cell Carcinoma	NO	Bristol-Myers Squibb Pharma EEIG	13 Jul 2011
Metastatic melanoma	EU	Bristol-Myers Squibb Pharma EEIG	13 Jul 2011
Metastatic melanoma	IS	Bristol-Myers Squibb Pharma EEIG	13 Jul 2011
Metastatic melanoma	LI	Bristol-Myers Squibb Pharma EEIG	13 Jul 2011
Metastatic melanoma	NO	Bristol-Myers Squibb Pharma EEIG	13 Jul 2011
metastatic non-small cell lung cancer	EU	Bristol-Myers Squibb Pharma EEIG	13 Jul 2011
metastatic non-small cell lung cancer	IS	Bristol-Myers Squibb Pharma EEIG	13 Jul 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Hepatocellular Carcinoma	NDA/BLA	CN	Bristol-Myers Squibb Pharma EEIG	13 Jul 2024
Bladder Cancer	Phase 3	US	Ono Pharmaceutical Co., Ltd.	30 Jan 2022
Bladder Cancer	Phase 3	US	Sino-American Shanghai Squibb Pharmaceuticals Ltd.	30 Jan 2022
HER2 negative Gastric Cancer	Phase 3	JP	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
HER2 negative Gastric Cancer	Phase 3	KR	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
HER2 negative Gastric Cancer	Phase 3	TW	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
Glioblastoma	Phase 3	US	National Cancer Institute	01 Sep 2020
Gliosarcoma	Phase 3	US	National Cancer Institute	01 Sep 2020
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	US	Bristol Myers Squibb Co.	08 Oct 2019
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	CN	Bristol Myers Squibb Co.	08 Oct 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01919619 (CTgov)	Phase 2	T-Cell Lymphoma \| Multiple Myeloma \| Leukemia	41	Lenalidomide+Ipilimumab (Autologous -Treatment (Lenalidomide and Ipilimumab))	bhucbmzjvx(rzeqiwfeav) = rtcdfhehrz icewfpgloe (ateeuhtlcf, oyaygzzdrf - mevtsznupx) View more	-	03 Dec 2024
				Lenalidomide+Ipilimumab (Allogeneic - Treatment (Lenalidomide and Ipilimumab))	bhucbmzjvx(rzeqiwfeav) = qmyrygdjps icewfpgloe (ateeuhtlcf, pkhobduktu - qsnmdbpmlk) View more
NCT03015740 (CTgov)	Phase 1/2	Locally Advanced Clear Cell Renal Cell Carcinoma \| Urothelial carcinoma bladder stage IV \| Non-small cell lung cancer stage III	42	Nivolumab+Sitravatinib (Received Sitravatinib 80 mg in Combination With Nivolumab)	jolwqxlclh(gkboigphxn) = jhltfyjruj nvdmmshinl (vlkvgeaqnx, zpvlkpirwr - eniolsjdmk) View more	-	19 Nov 2024
				Nivolumab+Sitravatinib (Received Sitravatinib 120 mg in Combination With Nivolumab)	jolwqxlclh(gkboigphxn) = uciniolxmo nvdmmshinl (vlkvgeaqnx, zhnpvsppcz - iytvmtfqnd) View more
NCT03575793 (BTCRC-LUN17-127, CTgov)	Phase 1/2	Recurrent Lung Small Cell Carcinoma	39	Ipilimumab+Nivolumab+Plinabulin	ozprirwtel(xximetaktm) = yzblswlrvq eqptlsljas (djsqzmkggs, whcbkgtysn - pzjfdvuwnp)	-	12 Nov 2024
NCT02046733 (ETOP/IFCT 4-12 STIMULI \| STIMULI, CTgov)	Phase 2	Small Cell Lung Cancer	222	ipilimumab+nivolumab (Observation)	xvrbyzmebp(lexpqyhrro) = jpfiwppsvd zabkzgvudf (aufskaurvz, ylddpaogdz - umnvehstxm) View more	-	08 Nov 2024
				Ipilimumab+nivolumab (Nivolumab + Ipilimumab)	xvrbyzmebp(lexpqyhrro) = qropdcsmxo zabkzgvudf (aufskaurvz, fvynupdmbx - zwdczkokol) View more
NCT02397720 (CTgov)	Phase 2	Relapsing acute myeloid leukemia \| Treatment related acute myeloid leukaemia \| Chronic Myelomonocytic Leukemia ... View more	150	nivolumab+Azacitidine (Arm 1 A Lead-In (Azacitidine, Nivolumab))	ikuwctdnwb(euiwwlwktr) = vqoxbrbotl lqtydxqkhi (rdnmrwvnzl, ucbvpejbpt - khtaskcvem) View more	-	04 Nov 2024
				Ipilimumab+nivolumab+Azacitidine (Arm 2 A Lead-In (Azacitidine, Nivolumab, Ipilimumab))	ikuwctdnwb(euiwwlwktr) = ntsvvqkzba lqtydxqkhi (rdnmrwvnzl, bjmuxhjhcp - bitnghduyi) View more
NCT03929029 (CTgov)	Phase 1	Melanoma, Cutaneous Malignant	11	Montanide+Ipilimumab+Nivolumab+NeoVax (Nivolumab, NeoVax + Montanide, Ipilimumab (2.5 mg Per Injection Site))	rziqdxzxgt(fjwdumddfz) = oiirhrlmpz hvvbxmxcbq (hflrtyhzqm, ewwmnjgwbb - wqcpbjiulb) View more	-	31 Oct 2024
				Montanide+Ipilimumab+Nivolumab+NeoVax (Nivolumab, NeoVax + Montanide, Ipilimumab (5.0 mg Per Injection Site))	rziqdxzxgt(fjwdumddfz) = dicxntfnhf hvvbxmxcbq (hflrtyhzqm, awnoqyrwtv - bufcwkntgh) View more
NCT02833233 (CTgov)	Not Applicable	Early Stage Breast Carcinoma	5	Cryoablation+ipilimumab+Nivolumab	tobphaqavu(hdqxwfczou) = fiidorhgex ddyelwarwv (qirtfytmjk, mozyltdqfc - nigedsgzdo) View more	-	23 Oct 2024
NCT00636168 \| NCT02388906 (Pubmed \| J Clin Oncol) Manual	Phase 3	Melanoma Adjuvant	-	Nivolumab (NIVO)	yyoiiicqpa(vcwsrprccx) = dwaawtndes uhkvltunxy (aqjbddocdb, 41.8 - 54.9)	Positive	08 Oct 2024
				Ipilimumab (IPI)	yyoiiicqpa(vcwsrprccx) = cclrwicwpu uhkvltunxy (aqjbddocdb, 32.7 - 44.1)
NCT02027935 (CTgov)	Phase 2	Metastatic melanoma	16	Autologous CD8+ Melanoma Specific T Cells+ipilimumab+Cyclophosphamide+Aldesleukin	cvjostfuan(gzapbjxcex) = tzugchufuc pwplhxllyq (zzgfcnnhqv, pgbcjdojsj - uhotmlmdtp) View more	-	08 Oct 2024
NCT03138512 (CheckMate 914, Pubmed \| J Clin Oncol) Manual	Phase 3	Renal Cell Carcinoma Adjuvant	825	Nivolumab	gwxlpnaeiu(wmmykesfpu) = the median DFS was not reached in either arm. zvmisdcbwn (ohgthaynra )	Negative	20 Sep 2024
				Placebo